Published in J Exp Med on May 01, 1986
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
Macrophage deactivation by interleukin 10. J Exp Med (1991) 6.94
Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A (1987) 6.76
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol (1987) 5.25
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest (1992) 4.49
Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med (1987) 4.35
Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med (1987) 4.35
Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol Cell Biol (1999) 3.55
Regulation of the inflammatory response in cardiac repair. Circ Res (2012) 3.21
Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci U S A (1991) 3.19
Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A (1993) 3.16
Transforming growth factor beta specifically enhances IgA production by lipopolysaccharide-stimulated murine B lymphocytes. J Exp Med (1989) 3.06
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med (1993) 3.06
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
Distribution and modulation of the cellular receptor for transforming growth factor-beta. J Cell Biol (1987) 2.87
Expression of transforming growth factor-beta 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol (1989) 2.77
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci U S A (1988) 2.69
Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta). J Exp Med (1991) 2.68
Cytokines in asthma. Thorax (1999) 2.64
Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Natl Acad Sci U S A (1988) 2.62
Inhibitory action of transforming growth factor beta on endothelial cells. Proc Natl Acad Sci U S A (1987) 2.50
Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest (1986) 2.40
Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol (2010) 2.35
Cell growth cycle block of T cell hybridomas upon activation with antigen. J Exp Med (1987) 2.30
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology (2006) 2.26
Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells. Mol Cell Biol (1987) 2.26
Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J (1987) 2.23
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol (1990) 2.19
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J Exp Med (1990) 2.19
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest (1991) 2.18
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest (1989) 2.16
Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol (1993) 2.16
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci U S A (1996) 2.15
Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest (1991) 2.11
Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med (1990) 2.09
Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol (1990) 2.09
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. Proc Natl Acad Sci U S A (1988) 2.03
'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev (2007) 1.98
Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology (1997) 1.95
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity (2009) 1.94
Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev (2004) 1.92
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov (2013) 1.90
Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest (1992) 1.82
Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med (2001) 1.82
Transforming growth factor-beta. Murine glomerular receptors and responses of isolated glomerular cells. J Clin Invest (1989) 1.82
Developmental expression of transforming growth factors alpha and beta in mouse fetus. Mol Cell Biol (1988) 1.79
Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med (1989) 1.77
Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A (1993) 1.76
Dysfunctional T regulatory cells in multiple myeloma. Blood (2005) 1.72
Autocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation. Immunity (2011) 1.72
Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. J Cell Biol (1993) 1.71
Bacterial cell wall-induced immunosuppression. Role of transforming growth factor beta. J Exp Med (1988) 1.64
TGF-β activation and function in immunity. Annu Rev Immunol (2013) 1.63
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci U S A (1991) 1.63
T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J (1987) 1.59
Aging and Cardiac Fibrosis. Aging Dis (2011) 1.58
Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med (2009) 1.57
Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J Exp Med (1993) 1.56
Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1990) 1.55
Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia. J Exp Med (1991) 1.55
Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol (1991) 1.55
Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res (2006) 1.54
Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg9-bradykinin. Br J Pharmacol (1988) 1.53
In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci U S A (1997) 1.53
Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med (1993) 1.52
Induction of transforming growth factor beta 1 by purified protein derivative of Mycobacterium tuberculosis. Infect Immun (1995) 1.52
Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. Proc Natl Acad Sci U S A (1993) 1.52
Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J Exp Med (2003) 1.52
Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer (1988) 1.51
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
Transforming growth factor beta suppresses human immunodeficiency virus expression and replication in infected cells of the monocyte/macrophage lineage. J Exp Med (1991) 1.43
CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis. J Clin Invest (2003) 1.41
Role of transforming growth factor-beta in hematologic malignancies. Blood (2006) 1.41
Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion. J Exp Med (1995) 1.41
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg (1995) 1.40
Beta transforming growth factors are potential regulators of B lymphopoiesis. J Exp Med (1987) 1.39
Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-beta 1. Am J Pathol (1995) 1.37
Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest (1990) 1.36
Review of the activation of TGF-beta in immunity. J Leukoc Biol (2008) 1.35
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol (2005) 1.35
TGF-beta and 'adaptive' Foxp3(+) regulatory T cells. J Mol Cell Biol (2009) 1.34
Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med (1992) 1.33
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther (2015) 1.33
Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med (1973) 11.59
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
T-cell growth factor. Immunol Rev (1980) 8.11
Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 5.93
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
The function and interrelationships of T-cell receptors, Ir genes and other histocompatibility gene products. Transplant Rev (1975) 5.88
Transient expression of interleukin 2 receptors. Consequences for T cell growth. J Exp Med (1983) 5.82
Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science (1984) 5.20
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci U S A (1984) 4.78
Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc Natl Acad Sci U S A (1981) 4.50
Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem (1984) 4.20
Interleukin 2 regulates its own receptors. Proc Natl Acad Sci U S A (1985) 4.19
Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci U S A (1982) 3.88
The fibroblast and wound repair. Biol Rev Camb Philos Soc (1968) 3.78
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A (1985) 3.74
Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science (1984) 3.53
Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci U S A (1983) 3.52
Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science (1983) 3.51
Purification and properties of a type beta transforming growth factor from bovine kidney. Biochemistry (1983) 3.49
Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc (1983) 3.31
The role of mitogenic lectins in T-cell triggering. Nature (1979) 3.26
Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A (1983) 3.02
Specific binding to cultured cells of 125I-labeled type beta transforming growth factor from human platelets. Proc Natl Acad Sci U S A (1984) 3.01
Separate signals for human B cell proliferation and differentiation in response to Staphylococcus aureus: evidence for a two-signal model of B cell activation. J Immunol (1982) 2.48
Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc Natl Acad Sci U S A (1982) 2.42
Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell (1984) 2.30
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Lymphocyte modulation of fibroblast function in vitro: stimulation and inhibition of collagen production by different effector molecules. J Immunol (1984) 2.18
Mechanism of T cell activation. II. Antigen- and lectin-dependent acquisition of responsiveness to TCGF is a nonmitogenic, active response of resting T cells. J Immunol (1981) 2.10
Further study of beta-TGFs released by virally transformed and non-transformed cells. Int J Cancer (1985) 1.77
Density-dependent regulation of growth of BSC-1 cells in cell culture: growth inhibitors formed by the cells. Proc Natl Acad Sci U S A (1978) 1.66
A murine T cell receptor gene complex: isolation, structure and rearrangement. Immunol Rev (1984) 1.56
Transferrin can replace serum for in vitro growth of mitogen-stimulated T lymphocytes. Eur J Immunol (1979) 1.53
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A (1986) 12.14
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem (1983) 9.32
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
Regulation of immune responses by TGF-beta. Annu Rev Immunol (1998) 8.01
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A (1987) 6.76
Expression of human immune interferon cDNA in E. coli and monkey cells. Nature (1982) 6.55
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol (1994) 6.00
Autocrine growth factors and cancer. Nature (1985) 5.97
Takayasu arteritis. Ann Intern Med (1994) 5.94
Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A (1985) 5.93
New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A (1981) 5.89
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 5.58
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J (1999) 5.49
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell (1984) 5.39
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature (1996) 5.30
Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol (1987) 5.25
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Transforming growth factor-beta: biological function and chemical structure. Science (1986) 5.08
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene (2000) 4.90
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol (2001) 4.87
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (1995) 4.56
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Can dietary beta-carotene materially reduce human cancer rates? Nature (1981) 4.43
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem (1984) 4.20
Production and auto-induction of transforming growth factor-alpha in human keratinocytes. Nature (1987) 4.19
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Mapping of transforming growth factor alpha gene on human chromosome 2 close to the breakpoint of the Burkitt's lymphoma t(2;8) variant translocation. Cancer Res (1985) 4.17
Isolation and structure of a human fibroblast interferon gene. Nature (1980) 4.16
Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature (1998) 4.13
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science (1987) 4.03
Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem (1988) 3.91
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80